Coronado, Gloria D. http://orcid.org/0000-0003-1130-6542
Nielson, Carrie M. http://orcid.org/0000-0002-2619-7839
Keast, Erin M.
Petrik, Amanda F. http://orcid.org/0000-0002-8891-6042
Suls, Jerry M. http://orcid.org/0000-0002-8436-7488
Clinical trials referenced in this document:
Documents that mention this clinical trial
Strategies and Opportunities to STOP Colon Cancer in Priority Populations: Design of a cluster-randomized pragmatic trial
https://doi.org/10.1016/j.cct.2014.06.006
The influence of multi-morbidities on colorectal cancer screening recommendations and completion
https://doi.org/10.1007/s10552-021-01408-2
Funding for this research was provided by:
Division of Cancer Epidemiology and Genetics, National Cancer Institute (UH3CA188640)
Article History
Received: 2 October 2019
Accepted: 23 February 2021
First Online: 9 March 2021
Declarations
:
: Dr. Coronado served as a co-investigator on a study funded by Epigenomics and as a principal investigator on a study funded by Quidel Corporation. Dr. Coronado also served as a scientific advisor for Exact Sciences and Guardant Health. The studies had no influence on the design, conduct, or reporting of the present study. All other authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (The Institutional Review Board of Kaiser Permanente Northwest; ClinicalTrials.gov registration: NCT01742065) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Institutional Review Board of Kaiser Permanente Northwest approved all study activities, and participating clinics ceded human subjects review authority to this IRB.
: Informed consent was obtained from all individual participants included in the study.